Jennifer A Grabowsky|Jennifer A. Baldock

Jennifer A Grabowsky|Jennifer A. Baldock

University of California San Francisco - San Francisco / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 1878288
person_outline Jennifer A Grabowsky|Jennifer A. Baldock's MOST POPULAR ARTICLES
1-) Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAI Daud, MT Ashworth, J Strosberg, JW Goldman, D Mendelson, ...J Clin Oncol 33 (9), 1060-6, 20151662015
2-) Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignanciesR Aggarwal, S Thomas, N Pawlowska, I Bartelink, J Grabowsky, T Jahan, ...Journal of Clinical Oncology 35 (11), 1231, 2017842017
3-) A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with …JC Bendell, RK Kelley, KC Shih, JA Grabowsky, E Bergsland, S Jones, ...Cancer 121 (19), 3481-3490, 2015842015
4-) Differential toxicity in patients with and without DNA repair mutations: phase I study of carboplatin and talazoparib in advanced solid tumorsMS Dhawan, IH Bartelink, RR Aggarwal, J Leng, JZ Zhang, N Pawlowska, ...Clinical Cancer Research 23 (21), 6400-6410, 2017652017
5-) Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlatesRK Kelley, HS Nimeiri, PN Munster, MT Vergo, Y Huang, CM Li, J Hwang, ...Annals of oncology 24 (7), 1900-1907, 2013612013